(Circulation. 1997;96:2332-2338.)
© 1997 American Heart Association, Inc.
Articles |
From the Experimental Cardiology Laboratory, Cardiovascular Division, Department of Medicine, University of Virginia, Charlottesville.
Correspondence to David K. Glover, Experimental Cardiology Laboratory, Cardiovascular Division, Department of Medicine, University of Virginia, Health Sciences Center Box 158, Charlottesville, VA 22908. E-mail dglover{at}virginia.edu
| Abstract |
|---|
|
|
|---|
Methods and Results EF was calculated in 4 anesthetized, open-chest dogs after intracoronary administration of 125I-labeled albumin and 99mTc-tetrofosmin. In another 16 dogs with either critical (n=6) or mild (n=10) left anterior descending coronary artery (LAD) stenoses, 201Tl and 99mTc-tetrofosmin were administered during adenosine infusion (250 µg · kg-1 · min-1). Dogs were killed 5 minutes later, and tracer activities were determined by ex vivo imaging of heart slices and by well counting. Mean 99mTc-tetrofosmin EF was 54.0±3.7%. In the 6 critical-stenosis dogs, the LAD-to-left circumflex artery (LCx) microsphere flow ratio was 0.22±0.02 with adenosine. The LAD-to-LCx activity ratios were 0.37±0.04 for 201Tl and 0.67±0.05 for 99mTc-tetrofosmin (P<.01). For the 10 mild-stenosis dogs, the LAD-to-LCx flow ratio was 0.44±0.05. The 201Tl activity ratio was 0.58±0.04, compared with 0.81±0.04 for 99mTc-tetrofosmin (P<.01). Thus, in both groups, 99mTc-tetrofosmin uptake underestimated the flow disparity more than 201Tl. Similarly, magnitudes of ex vivo image defects were significantly greater for 201Tl than for 99mTc-tetrofosmin in both groups.
Conclusions In this canine model, relative underperfusion with adenosine stress is better resolved with 201Tl than with 99mTc-tetrofosmin and may be explained by the lower EF for 99mTc tetrofosmin. With clinical imaging, greater 201Tl attenuation and redistribution may lessen this advantage.
Key Words: adenosine technetium thallium
| Introduction |
|---|
|
|
|---|
We previously reported that with adenosine-induced hyperemic flow in a canine stenosis model, both 201Tl and 99mTc-sestamibi significantly underestimated the magnitude of the flow disparity between stenotic and normal perfusion beds.13 The degree of underestimation was greater for 99mTc-sestamibi. The purpose of the present study was to directly compare 99mTc-tetrofosmin with 201Tl uptake during adenosine-induced vasodilatation in dogs with various degrees of coronary stenosis. A secondary objective was to quantify the first-pass myocardial EF of 99mTc-tetrofosmin in dogs. As previously shown for 99mTc-sestamibi, we hypothesized that myocardial 99mTc-tetrofosmin uptake would underestimate the adenosine-induced flow disparity between stenotic and normal beds. This underestimation might be greater for 99mTc-tetrofosmin than either 201Tl or 99mTc-sestamibi if the first-pass EF is confirmed to be lower for 99mTc-tetrofosmin than for the other two tracers.
| Methods |
|---|
|
|
|---|
A thoracotomy was performed at the level of the fifth intercostal space, and the heart was suspended in a pericardial cradle. A flare-tipped polyethylene catheter was inserted into the left atrial appendage for continuous left atrial pressure measurements and as a site for the injection of radiolabeled microspheres. The LAD was then dissected free of the epicardium, and an ultrasonic flow probe (T201, Transonic Systems) and snare ligature were placed around the vessel. A similar flow probe was placed around the LCx.
The hemodynamic parameters of heart rate, systemic arterial and left atrial pressures, and LAD and LCx flows were continuously recorded on an 8-channel strip-chart recorder (7758D, Hewlett-Packard) throughout each protocol. All experiments were performed with the approval of the University of Virginia Animal Research Committee in compliance with the position of the American Heart Association on use of research animals.
Protocol 1: Determination of First-Pass EF of
99mTc-Tetrofosmin in Canine Myocardium in Dogs
With Normal Coronary Flow
The method used for measurement of the first-pass EF has been
described previously.14 For these experiments, 4
anesthetized open-chest dogs underwent LAD cannulation directly
with a 22-gauge needle-tipped catheter. A second catheter was inserted
into the right jugular vein and advanced until its tip rested in the
coronary sinus. The catheter was connected to a withdrawal pump
with a fixed withdrawal rate. An isotope mixture was prepared
containing 0.185 to 0.37 MBq (5 to 10 µCi) of
125I-labeled albumin and 0.74 to 1.11 MBq (20 to 30
µCi) of 99mTc-tetrofosmin, which was then diluted by a
factor of 20. A small aliquot of the dilute isotope mixture was
injected directly into the coronary artery while venous blood
was simultaneously withdrawn from the coronary
sinus catheter. For repeat measurements, the injectate volume was
doubled each time to overcome increasing background activity. The EF
was calculated by the formula (1)
(1) EF=[1-(99mTc-tetrofosminCSx125I-albumininj)]/
![]() |
Three to four repeat measurements of EF were made in each of the 4 dogs. To validate our technique, EF measurements were also made in 3 additional dogs with 99mTc-sestamibi, and the mean EF data obtained (68.3±4.7%) were similar to those previously reported by an independent laboratory.15
Protocol 2: Comparison of Myocardial Uptake of
99mTc-Tetrofosmin With That of 201Tl During
Adenosine-Induced Vasodilatation in Dogs With Critical and Mild
Coronary Stenoses
The experimental protocol is depicted in Fig 1
. During the baseline period, before the
mild or severe coronary stenoses were created,
radioactive microspheres were administered to measure baseline
flow as previously described. The reactive hyperemic response
of the LAD was determined by snaring of the occluder for 10 seconds and
then release of the snare to inscribe a reactive hyperemic
response on the recorder. For dogs with a critical
stenosis, the snare was adjusted to abolish the reactive
hyperemic response to this transient LAD occlusion without
reducing resting baseline flow. For dogs with a mild stenosis,
a 50% reduction in the reactive hyperemic response was the end
point. After the stenoses were set, a second injection of
microspheres was administered. Then, an intravenous
infusion of adenosine was begun at a rate of 250 µg ·
kg-1 · min-1.
When LCx flow was maximal, 18.5 MBq (0.5 mCi) of 201Tl and
296 MBq (8 mCi) of 99mTc-tetrofosmin and
microspheres were injected simultaneously. Five
minutes later, before 201Tl redistribution occurred, the
dogs were killed. The hearts were then removed and sliced into four
1-cm rings from apex to base. The heart slices were imaged directly on
the collimator of a gamma camera (model 420, TM Analytic) for maximal
count time (0.75x106 to 1.0x106 counts) with
99mTc window settings. The heart slices were left
undisturbed on the collimator until the following day and then reimaged
with 201Tl window settings for a similar count density. The
heart slice images were then quantified by regions of interest drawn on
the LAD defect area of the anteroseptal wall and on the normal
LCx-perfused posterior wall of the two midsection slices. The basal and
apical slices were not used for image quantification because the basal
slice is located above the coronary stenosis and rarely
has a defect, whereas the apical slice has a negligible normal area.
Defect magnitude was expressed as the ratio of the average counts in
the LAD region divided by the average counts in the LCx region.
|
After imaging of the slices, each slice was divided into six segments, which were further subdivided into endocardial, midwall, and epicardial samples, resulting in a total of 72 myocardial samples for each dog. Gamma-well counting was performed on these samples to determine 201Tl and 99mTc-tetrofosmin activities and microsphere flows. The instrumentation and techniques used were comparable to those reported previously.13 The tissue counts were corrected for background, decay, and isotope spillover, and regional myocardial blood flow was calculated with specialized computer software (PCGERDA, Packard Instruments). Transmural activity and flow values were calculated as the average of the corresponding epicardial, midwall, and endocardial samples.
Data Analysis and Statistics
For each of the 16 individual dogs, raw data plots of
201Tl and 99mTc-tetrofosmin activities versus
microsphere flow at the time of injection during
adenosine stress were created with all 72 tissue segments from
each dog. A plot of data pooled from all 6 critical-stenosis
dogs (Fig 4
) was created by normalizing the activity data from each
individual dog to the activity of a segment in the same dog with a
normal flow of
1.0 mL ·
min-1 ·
g-1.
|
Representative tissue segments from the LAD and LCx regions were then selected by definition of the LAD (stenotic) region as the 10% of transmural segments (3 transmural segments=9 tissue segments) with the lowest flow at the time of adenosine stress, whereas the LCx (normal) region was defined as the 10% of segments (an additional 9 tissue segments) with the highest adenosine flows.
All statistical computations were made with SYSTAT software. The results were expressed as mean±SEM. Differences between means within a group were assessed with repeated-measures ANOVA (hemodynamics) or a paired t test (201Tl versus 99mTc-tetrofosmin image count ratios), with values of P<.05 considered significant. Comparisons between the two groups were made with one-way ANOVA.
| Results |
|---|
|
|
|---|
Protocol 2: Comparison of the Myocardial Uptake of
99mTc-Tetrofosmin and 201Tl During
Adenosine-Induced Vasodilatation
Hemodynamics
The mean hemodynamic parameters of
heart rate, arterial pressure, and left atrial pressure are
summarized in Table 1
. Note that although
there was a significant decrease in mean arterial pressure
with adenosine in both groups of dogs (critical, 116±4 to
93±5; mild, 122±5 to 103±5; P<.01 for both), as was
found in our previous studies13 using the 250 µg
· kg-1 ·
min-1 adenosine dose rate,
arterial pressure remained >90 mm Hg at the peak
adenosine response at the time when the tracers were
administered. There were no significant changes in heart rate or left
atrial pressure over the experimental time course.
|
Figs 2
(critical-stenosis dogs)
and 3 (mild-stenosis dogs) depict
the ultrasonically measured flow in the LAD and LCx, respectively. In
both figures, the solid bar represents mean baseline flow, the
hatched bar represents mean flow after the LAD stenosis
was set, and the open bar represents mean flow at the peak
adenosine response when 201Tl and
99mTc-tetrofosmin were injected. As can be seen, in both
groups of dogs, no change in resting flow was seen after the LAD
stenosis was set. In the critical-stenosis group (Fig 2
), adenosine infusion resulted in no increase in LAD flow but
in a greater than threefold increase in LCx flow. In the
mild-stenosis group (Fig 3
), there was a significant
(P<.01) increase in both LAD and LCx flows, but the
magnitude of the LCx flow increase was significantly greater than that
of the LAD.
|
|
Regional 99mTc-Tetrofosmin and 201Tl
Activities Versus Microsphere Flow
The graph shown in Fig 4
from the
group of dogs with a critical stenosis plots the normalized
201Tl and 99mTc-tetrofosmin activity values
from the endocardial, midwall, and epicardial myocardial segments
versus microsphere flow at the time when the tracers were
injected during adenosine vasodilatation. The curves passing
through each set of data points result from mathematical modeling of
the experimental data according to the kinetic transport model of
Gosselin and Stibitz.16 As shown, the myocardial uptake of
both 201Tl and 99mTc-tetrofosmin reached a
plateau as coronary flow increased. However, the more rapid and
lower plateau for 99mTc-tetrofosmin indicates a greater
diffusion limitation at high flow rates for this tracer.
Mean absolute transmural flow in the LAD and LCx zones and the
transmural LAD-to-LCx flow ratios from both groups of dogs are shown in
Table 2
. The transmural values were
calculated as the weighted average of the endocardial, midwall, and
epicardial segments from each region. Although there was a trend toward
higher mean LCx transmural flow with adenosine in the mild-
versus critical-stenosis groups of dogs, this difference did
not reach statistical significance. Fig 5
compares the transmural LAD-to-LCx activity ratios for
201Tl and 99mTc-tetrofosmin with the
microsphere flow ratio at the time when the tracers were
administered during adenosine vasodilatation. The bars on the
left are from the critical-stenosis group of dogs, whereas
those on the right are from the mild-stenosis group. The
LAD-to-LCx flow ratio fell from 0.96 with the stenosis in place
to 0.22 during adenosine infusion (P<.001) in the
critical-stenosis group. Similarly, the LAD-to-LCx flow ratio
fell from 0.92 with the stenosis alone to 0.44 during
adenosine infusion in the mild-stenosis group. Note
that in both groups of dogs, both 201Tl (critical,
0.37±0.04; mild, 0.58±0.04) and 99mTc-tetrofosmin
(critical, 0.67±0.05; mild, 0.81±0.04) significantly underestimated
the degree of flow disparity (critical, 0.22±0.02; mild, 0.44±0.05;
P<.01 versus 201Tl and
99mTc-tetrofosmin); however, the magnitude of
underestimation was greater for 99mTc-tetrofosmin
(P<.01).
|
|
Ex Vivo Imaging
Representative 201Tl and
99mTc-tetrofosmin images from dogs with either critical or
mild LAD stenoses are shown in Fig 6
. Qualitatively, defects on images were
more pronounced with 201Tl than with
99mTc-tetrofosmin in all 16 dogs. The quantitative imaging
results showing mean image LAD-to-LCx count ratios for
201Tl and 99mTc-tetrofosmin are summarized in
Fig 7
. In both groups of dogs, the
magnitude of the image defects (lower count ratios) was significantly
greater for 201Tl (critical, 0.61±0.01; mild, 0.74±0.03)
than for 99mTc-tetrofosmin (critical, 0.69±0.02; mild,
0.83±0.02) (P<.05; P<.01).
|
|
| Discussion |
|---|
|
|
|---|
Previous Experimental Studies
The findings of the present study are also consistent
with previously published reports of decreased myocardial uptake of
cationic radiolabeled perfusion agents with increased coronary
flow consequent to infusion of dipyridamole or
adenosine.19 20 21 22 Sinusas et al2
administered 99mTc-tetrofosmin and radiolabeled
microspheres during intravenous adenosine
infusion to 6 dogs with complete occlusion of the LAD.
99mTc-tetrofosmin reached a plateau at flows >2.0 mL
· min-1 ·
g-1. Myocardial 99mTc-tetrofosmin
activity correlated linearly with microsphere flow at the time
of injection up to 2.0 mL · min-1
· g-1. In the present study,
99mTc-tetrofosmin was administered
intravenously during vasodilator stress in the setting of
critical or mild LAD stenoses and compared with uptake of
201Tl, a monovalent cation with a high first-pass EF. As
shown in Fig 4
, myocardial 99mTc-tetrofosmin uptake is
almost flat at 1.5 times normal flow, whereas uptake of
201Tl continues to show an increase relative to
hyperemic flows over the entire range, although flows are also
underestimated in the range shown up to 5 times normal flow.
Furthermore, the in vitro well-counting data and the ex vivo imaging
data from this study suggest that reduced defect contrast with
99mTc-tetrofosmin should be observed with clinical imaging
in patients, particularly in the setting of mild coronary
stenoses, in which it is often necessary to resolve the
difference between two hyperemic flow rates (eg, 2.0 times
normal versus 4.0 times normal flow). Severe stenoses, however,
should be well resolved with 99mTc-tetrofosmin because, in
this situation, tracer uptake in zones of hyperemia are being
compared with uptake in the stenotic myocardial bed, in which
flow does not increase or may actually decrease in the endocardial
layers consequent to vasodilator-induced coronary steal.
Transport Kinetics of 99mTc-Tetrofosmin
The findings of the present study are consistent with
mathematical models of transport kinetics of any diffusible indicator.
The curves shown in Fig 4
are characteristic of an extractable tracer
in that the amount of tracer taken up is proportional to flow only at
low flow rates and changes to a plateau at high flow rates when the
extraction becomes limited by membrane transport. At high flows, less
tracer is directly extracted during the capillary transit, and the
tracer that diffuses back into the capillary channel is less likely to
be reabsorbed before it reaches the venous bed. The lower the
first-pass EF of a tracer, the less the tracer is extracted at these
hyperemic flows, and vasodilator-induced flow increases will be
underestimated.
The heavy solid and dashed lines, with 95% CIs, passing through the
201Tl and 99mTc-tetrofosmin values in Fig 4
are
based on the solute transport model of Gosselin and
Stibitz.16 In this model, the rate of tracer transport
from blood to the extravascular space as the tracer passes through the
capillary bed is given by Equation
2: (2) (dm/dt)=(nb/
)(1-e-ps/b)(Ca-m)
where m is tissue tracer concentration, n is number of open
capillaries per unit volume,
is intracellular/extracellular
partition coefficient, b is blood flow per unit volume, ps is
permeabilityxsurface area product, and Ca is
arterial tracer concentration.
To apply this model to the measurements of 201Tl or 99mTc-tetrofosmin extraction, the meaning of the term "extraction" must be carefully considered. When an extractable tracer is delivered to a capillary bed, the amount extracted changes continuously with time. The capillary membrane is exposed to a variable concentration of tracer from the arterial input. As the tracer passes through the capillary bed, some is extracted, and some of the tracer that has been extracted is released back into the vascular compartment (ie, back-diffusion). The amount of tracer extracted depends on the net balance between cellular extraction and release and is never constant. An estimate of early extraction that fairly describes what is being measured can be determined. If an impulse arterial input function in Equation 2 is considered, then the amount of tracer extracted from the impulsive input is proportional to the factor (3) b(1-e-ps/b)
For a more realistic estimate, an exponential arterial input function with a time constant that is short in comparison to the intrinsic intracellular clearance rate may be considered. In this case, the solution to Equation 2 becomes a multiple exponential with a rapid upslope to a peak level followed by a washout phase. The amplitude of the uptake/washout curve is still proportional to the same factor (Equation 3). If a measurement of myocardial activity is undertaken after the injected bolus has mostly cleared from the arterial blood but before there has been a substantial loss of initially extracted tracer from the myocardium, the amount of net extracted tracer can be expected to follow approximately the relationship predicted above.
Clinical Studies
Clinically, 99mTc-tetrofosmin imaging with exercise
stress has yielded good sensitivity and specificity for detection of
coronary artery disease, and segmental perfusion abnormalities
have shown good concordance with defects on 201Tl imaging
performed in the same patients.5 6 7 8 9 10 11 When images were
compared, image quality was better for 99mTc-tetrofosmin
than for 201Tl.6 10 11 23 However, some
published studies10 11 had a substantial number of
patients with previous infarction, which enhances sensitivity of
noninvasive imaging for detection of coronary artery disease.
Also, because many patients presenting with angina have at least
one high-grade coronary stenosis that may be comparable
physiologically to the "critical"
stenoses experimentally produced in the groups of dogs in the
present study, it is not surprising that
99mTc-tetrofosmin imaging with exercise stress yields a
high rate of detection of patients with coronary artery
disease. Furthermore, with clinical imaging, greater redistribution and
scatter with 201Tl compared with
99mTc-tetrofosmin would tend to lessen somewhat the
advantage of 201Tl over 99mTc-tetrofosmin seen
in our experimental canine model, in which defect contrast for
201Tl on images of myocardial slices postmortem was
superior to that of 99mTc-tetrofosmin.
Conversely, the lower EF and the greater plateau in myocardial uptake with increases in flow for 99mTc-tetrofosmin versus 201Tl may, indeed, affect defect magnitude or size, as well as the detection rate of reversible ischemia. In a study by Matsunari et al,9 defect size on exercise 99mTc-tetrofosmin images was smaller than the 201Tl defect size as assessed by quantitative SPECT imaging in 20 patients with coronary artery disease. In these patients, 58 segments with initial 201Tl defects had corresponding normal 99mTc-tetrofosmin uptake. Tamaki et al6 reported better 201Tl than 99mTc-tetrofosmin defect magnitude, particularly in regions corresponding to exercise-induced ischemic 201Tl defects. Nevertheless, both the 99mTc-tetrofosmin and 201Tl studies were highly sensitive for detecting coronary artery disease (100% and 94%, respectively).
Other clinical studies have reported a higher detection rate for
reversible ischemia on exercise scintigraphy for
201Tl versus 99mTc-tetrofosmin. Nakajima et
al5 reported a 60% detection rate of
75%
stenoses for 99mTc-tetrofosmin versus 72% for
201Tl, with comparable specificities of 84%. In the phase
III multicenter 99mTc-tetrofosmin trial, there was a 13%
greater detection of ischemia or ischemia with scar
with 201Tl than with
99mTc-tetrofosmin.10 In another study by
Matsunari et al,24 it was reported that 40% of scan
segments were discordant between 201Tl and
99mTc-tetrofosmin perfusion images when exercise-rest
99mTc-tetrofosmin images were compared with
exercise-redistribution-reinjection 201Tl images. Of the
115 segments with reversible defects identified by 201Tl
imaging, 73 (63%) were identified as nonreversible on
99mTc-tetrofosmin images. In contrast, of the 94 segments
with nonreversible defects identified by 201Tl imaging,
only 11 (12%) were documented as reversible by
99mTc-tetrofosmin. In addition, in that study, exercise
defect severity was also less with
99mTc-tetrofosmin.
All of the clinical studies referenced above involve exercise stress. At present, few quantitative, comparative studies of patients undergoing pharmacological stress imaging with 99mTc-tetrofosmin have been reported. In one recent study, Cuocolo et al25 reported that exercise-induced defects on 99mTc-tetrofosmin imaging were more severe than on adenosine stress images when exercise and vasodilator images acquired in the same patients were compared. More recently, preliminary data from Raggi et al26 suggest that more reversible or partially reversible perfusion defects were identified on dipyridamole 201Tl SPECT images than on dipyridamole 99mTc-tetrofosmin images (89 versus 55) when 340 interpretable scan segments were analyzed in 26 patients. This difference was seen in myocardial regions perfused by vessels with 50% to 70% stenoses on quantitative angiography. The initial postdipyridamole defect magnitude of these reversible defects was significantly greater on the 201Tl SPECT images than on the corresponding 99mTc-tetrofosmin images. In contrast, the detection rate for myocardial scar and the defect magnitude in nonreversible defects were comparable for the two imaging agents.
Conclusions
99mTc-tetrofosmin uptake during
adenosine-induced hyperemic flow underestimated the
flow disparity between stenotic and normal perfusion beds in
dogs with critical and mild stenoses. The degree of
underestimation was greater than seen with 201Tl uptake
patterns in the same dogs. The clinical implication of these
experimental observations for vasodilator SPECT imaging remains to be
definitively determined, because such variables as greater
redistribution, more scatter, and greater attenuation with
201Tl could offset its advantage with respect to extraction
kinetics with high-flow states. Few clinical studies are available that
directly compare 201Tl and 99mTc-tetrofosmin
uptake during vasodilator stress in the absence of prior infarction,
although, as mentioned previously, some of the clinical imaging studies
published to date show high sensitivity and specificity for stress
imaging with 99mTc-tetrofosmin for detection of
coronary artery disease and identifying coronary
stenoses. In some studies, the detection rate of reversible
ischemia and defect magnitude on stress-induced perfusion
abnormalities is greater for 201Tl compared with
99mTc-tetrofosmin for both exercise and vasodilator stress.
Additional clinical research is needed that uses larger numbers of
patients and quantitative SPECT imaging to properly assess the
influence on clinical imaging studies of the experimental findings
reported in these canine models of severe and mild coronary
stenoses.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received February 6, 1997; revision received April 25, 1997; accepted May 3, 1997.
| References |
|---|
|
|
|---|
2.
Sinusas AJ, Shi Q, Saltzberg MT, Vitols P, Jain D,
Wackers FJ, Zaret BL. Technetium-99m-tetrofosmin to
assess myocardial blood flow: experimental validation in an intact
canine model of ischemia. J Nucl Med. 1994;35:664-671.
3. Platts EA, North TL, Pickett RD, Kelly JD. Mechanism of uptake of technetium-tetrofosmin, I: uptake into isolated adult rat ventricular myocytes and subcellular localization. J Nucl Cardiol. 1995;2:317-326.[Medline] [Order article via Infotrieve]
4. Younès A, Songadele JA, Maublant J, Platts E, Pickett R, Veyre A. Mechanism of uptake of technetium-tetrofosmin, II: uptake into isolated adult rat heart mitochondria. J Nucl Cardiol. 1995;2:327-333.[Medline] [Order article via Infotrieve]
5.
Nakajima K, Taki J, Shuke N, Bunko H, Takata S, Hisada
K. Myocardial perfusion imaging and dynamic analysis
with technetium-99m tetrofosmin. J Nucl
Med. 1993;34:1478-1484.
6.
Tamaki N, Takahashi N, Kawamoto M, Torizuka T,
Tadamura E, Yonekura Y, Okuda K, Nohara R, Sasayama S, Konishi
J. Myocardial tomography using
technetium-99m-tetrofosmin to evaluate coronary
artery disease. J Nucl Med. 1994;35:594-600.
7. Takahasi N, Tamaki N, Tadamura E, Kawamoto M, Torizuka T, Yonekura Y, Okuda K, Nohara R, Sasayama S, Konishi J. Combined assessment of regional perfusion and wall motion in patients with coronary artery disease with technetium 99m tetrofosmin. J Nucl Cardiol. 1994;1:29-38.[Medline] [Order article via Infotrieve]
8.
Rigo P, Leclercq B, Itti R, Lahiri A, Braat S.
Technetium-99m-tetrofosmin myocardial imaging: a comparison
with thallium-201 and angiography. J Nucl Med. 1994;35:587-593.
9. Matsunari I, Fujino S, Taki J, Senma J, Aoyama T, Wakasugi T, Hirai J, Saga T, Tonami N, Hisada K. Comparison of defect size between thallium-201 and technetium-99m tetrofosmin myocardial single-photon emission computed tomography in patients with single-vessel coronary artery disease. Am J Cardiol. 1996;77:350-354.[Medline] [Order article via Infotrieve]
10.
Zaret BL, Rigo P, Wackers FJ, Hendel RC, Braat SH,
Iskandrian AS, Sridhara BS, Jain D, Itti R, Serafini AN, Goris ML,
Lahiri A, Tetrofosmin International Trial Study Group. Myocardial
perfusion imaging with 99mTc tetrofosmin: comparison to
201Tl imaging and coronary angiography in a phase
III multicenter trial. Circulation. 1995;91:313-319.
11. Sridhara BS, Braat S, Rigo P, Itti R, Cload P, Lahiri A. Comparison of myocardial perfusion imaging with technetium-99m tetrofosmin versus thallium-201 in coronary artery disease. Am J Cardiol. 1993;72:1015-1019.[Medline] [Order article via Infotrieve]
12. Dahlberg ST, Gilmore MP, Leppo JA. Effect of coronary blood flow on the `uptake' of tetrofosmin in the isolated rabbit heart. J Nucl Med. 1992;5:846. Abstract.
13.
Glover DK, Ruiz M, Edwards NC, Cunningham M, Simanis
JP, Smith WH, Watson DD, Beller GA. Comparison between
201Tl and 99mTc sestamibi uptake during
adenosine-induced vasodilation as a function of
coronary stenosis severity.
Circulation. 1995;91:813-820.
14.
Moore CA, Cannon J, Watson DD, Kaul S, Beller
GA. Thallium 201 kinetics in stunned myocardium
characterized by severe postischemic systolic
dysfunction. Circulation. 1990;81:1622-1632.
15. Mousa SA, Cooney JM, Williams SJ. Relationship between regional myocardial blood flow and the distribution of 99mTc-sestamibi in the presence of total coronary artery occlusion. Am Heart J. 1990;119:842-847.[Medline] [Order article via Infotrieve]
16. Gosselin RE, Stibitz GR. Rates of solute absorption from tissue depots: theoretical considerations. Pflugers Arch. 1970;318:85-98.[Medline] [Order article via Infotrieve]
17.
Weich HF, Strauss HW, Pitt B. The extraction of
thallium-201 by the myocardium.
Circulation. 1977;56:188-191.
18.
Grunwald AM, Watson DD, Holzgrefe HH Jr, Irving JF,
Beller GA. Myocardial thallium-201 kinetics in normal and
ischemic myocardium.
Circulation. 1981;64:610-618.
19.
Glover DK, Okada RD. Myocardial kinetics of
Tc-MIBI in canine myocardium after
dipyridamole. Circulation. 1990;81:628-636.
20. Strauss HW, Pitt B. Noninvasive detection of subcritical coronary arterial narrowings with a coronary vasodilator and myocardial perfusion imaging. Am J Cardiol. 1976;39:403-406.
21. Mays AE, Cobb FR. Relationship between regional myocardial blood flow and thallium-201 distribution in the presence of coronary artery stenosis and dipyridamole-induced vasodilatation. J Clin Invest. 1984;73:1359-1366.
22.
Gerson MC, Millard RW, Roszell NJ, McGoron AJ, Gabel M,
Washburn LC, Biniakiewicz D, Blankenship D, Mallin WH, Elder RC,
Deutsch E, Walsh RA. Kinetic properties of 99mTc-Q12
in canine myocardium. Circulation. 1994;89:1291-1300.
23. Hendel RC, Parker MA, Wackers FJT, Rigo P, Lahiri A, Zaret BL. Reduced variability of interpretation and improved image quality with a technetium 99m myocardial perfusion agent: comparison of thallium 201 and technetium 99m-labeled tetrofosmin. J Nucl Cardiol. 1994;1:509-514.[Medline] [Order article via Infotrieve]
24.
Matsunari I, Fujino S, Taki J, Senma J, Aoyama T,
Wakasugi T, Hirai J, Saga T, Ichiyanagi K, Hisada K. Myocardial
viability assessment with technetium-99m-tetrofosmin and
thallium-201 reinjection in coronary artery disease.
J Nucl Med. 1995;36:1961-1967.
25. Cuocolo A, Nicolai E, Soricelli A, Pace L, Nappi A, Sullo P, Cardei S, Argenziano L, Ell PJ, Salvatore M. Technetium-99m-labeled tetrofosmin myocardial tomography in patients with coronary artery disease: comparison between adenosine and dynamic exercise stress testing. J Nucl Cardiol. 1996;3:194-203.[Medline] [Order article via Infotrieve]
26. Raggi P, Shanoudy H, Watson DD, Ammerman GE, Soliman A, Kastner RJ, Beller GA. Comparison of dipyridamole thallium-201 with dipyridamole technetium-99m tetrofosmin single photon emission computed tomography in patients with angiographically confirmed coronary artery disease. Circulation. 1996;94(suppl I):I-302. Abstract.
This article has been cited by other articles:
![]() |
O. Gaemperli, T. Schepis, I. Valenta, P. Koepfli, L. Husmann, H. Scheffel, S. Leschka, F. R. Eberli, T. F. Luscher, H. Alkadhi, et al. Functionally Relevant Coronary Artery Disease: Comparison of 64-Section CT Angiography with Myocardial Perfusion SPECT Radiology, August 1, 2008; 248(2): 414 - 423. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. P. Steele, D. L. Kirch, and J. E. Koss Comparison of Simultaneous Dual-Isotope Multipinhole SPECT with Rotational SPECT in a Group of Patients with Coronary Artery Disease J. Nucl. Med., July 1, 2008; 49(7): 1080 - 1089. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Madar, H. Ravert, A. DiPaula, Y. Du, R. F. Dannals, and L. Becker Assessment of Severity of Coronary Artery Stenosis in a Canine Model Using the PET Agent 18F-Fluorobenzyl Triphenyl Phosphonium: Comparison with 99mTc-Tetrofosmin J. Nucl. Med., June 1, 2007; 48(6): 1021 - 1030. [Abstract] [Full Text] [PDF] |
||||
![]() |
C Y Loong and C Anagnostopoulos Diagnosis of coronary artery disease by radionuclide myocardial perfusion imaging Heart, August 1, 2004; 90(suppl_5): v2 - v9. [Full Text] [PDF] |
||||
![]() |
A. F.L. Schinkel, A. Elhendy, R. T. van Domburg, J. J. Bax, J. R.T.C. Roelandt, and D. Poldermans Prognostic Value of Dobutamine-Atropine Stress 99mTc-Tetrofosmin Myocardial Perfusion SPECT in Patients with Known or Suspected Coronary Artery Disease J. Nucl. Med., June 1, 2002; 43(6): 767 - 772. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Fagret, C. Ghezzi, and G. Vanzetto 99mTc-N-NOET Imaging for Myocardial Perfusion: Can It Offer More Than We Already Have? J. Nucl. Med., September 1, 2001; 42(9): 1395 - 1396. [Full Text] [PDF] |
||||
![]() |
P. Soman, R. Taillefer, E. G. DePuey, J. E. Udelson, and A. Lahiri Enhanced detection of reversible perfusion defects by Tc-99m sestamibi compared to Tc-99m tetrofosmin during vasodilator stress SPECT imaging in mild-to-moderate coronary artery disease J. Am. Coll. Cardiol., February 1, 2001; 37(2): 458 - 462. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-X. He, E. Cwajg, W. Hwang, C. J. Hartley, E. Funk, L. H. Michael, and M. S. Verani Myocardial Blood Flow and Myocardial Uptake of 201Tl and 99mTc-Sestamibi During Coronary Vasodilation Induced by CGS-21680, a Selective Adenosine A2A Receptor Agonist Circulation, July 25, 2000; 102(4): 438 - 444. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |